Biomarkers for Diabetes Using Stem Cell-Derived Beta Cells
使用干细胞衍生的 β 细胞作为糖尿病生物标志物
基本信息
- 批准号:8813227
- 负责人:
- 金额:$ 159.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-23 至 2018-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAntibodiesApoptosisAutoantibodiesAutoimmune ProcessBeta CellBiological AssayBiological MarkersBloodBlood GlucoseCell DeathCell LineCellsCellular StressCessation of lifeClinicalClustered Regularly Interspaced Short Palindromic RepeatsCoculture TechniquesCodeDetectionDiabetes MellitusDiagnosisDiseaseEarly DiagnosisEarly identificationEngraftmentEventGenesGlucoseHealthHistocompatibility TestingHumanImmuneIn VitroInjection of therapeutic agentInsulinInsulin-Dependent Diabetes MellitusKidneyLipidsMass Spectrum AnalysisMeasuresMediatingMethodsMonitorMusPancreasPathogenesisPatientsPeptidesPluripotent Stem CellsProductionStagingStem cellsStressT-LymphocyteTestingTimeTissuesTranscriptbasebiological adaptation to stresscandidate markercapsulecell typecytokinediabetes controlimprovedin vivoinduced pluripotent stem cellinterestmolecular markernon-diabeticnovelresponsetranscriptome sequencing
项目摘要
DESCRIPTION (provided by applicant): The diagnosis of Type 1 diabetes (T1D) is currently limited by methods that detect the disease at relatively late stages, when blood glucose levels rise and autoimmune attack is well underway. By this stage, given the treatments presently available (insulin injection), the b cell loss is de facto, irreversible. Biomarkers for early detetion of β cell stress, before this late stage, would improve diagnosis and open up new windows to monitor and possibly treat the disease. We will produce functionally mature, "never-before-stressed", β cells from human pluripotent stem cells and use these cells to identify biomarkers for the earliest stages of β cell stress by providing various stress conditions ex vivo. In additin, we can use stem cells from T1D and control patients to investigate differences in their β ell responses to stress. In other words, we can ask: are β cells in T1D patients especially sensitive to stress or in other ways defective before an immune attack? Successful identification of early β ell-specific biomarkers for stress will enable earlier detection and diagnosis, better tracking f progress from asymptomatic to clinical presentation, and a more mechanistic understanding of the earliest stages and possibly initiating events of human T1D.
描述(由申请人提供):1型糖尿病(T1D)的诊断目前受到在相对晚期阶段检测疾病的方法的限制,此时血糖水平升高且自身免疫性攻击正在进行中。到了这个阶段,考虑到目前可用的治疗(胰岛素注射),B细胞损失事实上是不可逆的。在这个晚期阶段之前,早期检测β细胞应激的生物标志物将改善诊断,并为监测和可能治疗该疾病开辟新的窗口。我们将从人多能干细胞中产生功能成熟的、“从未受到应激”的β细胞,并通过离体提供各种应激条件,使用这些细胞来鉴定β细胞应激的最早阶段的生物标志物。此外,我们可以使用来自T1D和对照患者的干细胞来研究他们对压力的β细胞反应的差异。换句话说,我们可以问:T1D患者的β细胞是否对压力特别敏感,或者在免疫攻击之前有其他方面的缺陷?成功鉴定应激的早期β细胞特异性生物标志物将能够更早地检测和诊断,更好地跟踪从无症状到临床表现的进展,以及对人类T1D的最早阶段和可能的起始事件的更机械的理解。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
IAPP Marks Mono-hormonal Stem-cell Derived β Cells that Maintain Stable Insulin Production in vitro and in vivo.
IAPP 标记单激素干细胞衍生的 β 细胞,可在体外和体内维持稳定的胰岛素生产。
- DOI:10.1101/2024.04.10.587726
- 发表时间:2024
- 期刊:
- 影响因子:0
- 作者:Davis,JeffreyC;Ryaboshapkina,Maria;Kenty,JenniferH;Eser,PinarÖ;Menon,Suraj;Tyrberg,Björn;Melton,DouglasA
- 通讯作者:Melton,DouglasA
Purification of Live Stem-Cell-Derived Islet Lineage Intermediates.
- DOI:10.1002/cpsc.111
- 发表时间:2020-06-01
- 期刊:
- 影响因子:0
- 作者:Rasouli, Niloofar;Melton, Douglas A;Alvarez-Dominguez, Juan R
- 通讯作者:Alvarez-Dominguez, Juan R
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DOUGLAS A MELTON其他文献
DOUGLAS A MELTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DOUGLAS A MELTON', 18)}}的其他基金
Reconstruction of Human Type 1 Diabetes in Mice
在小鼠中重建人类 1 型糖尿病
- 批准号:
8183478 - 财政年份:2011
- 资助金额:
$ 159.31万 - 项目类别:
Regenerating Beta Cells by Lineage Reprogramming
通过谱系重编程再生β细胞
- 批准号:
8522193 - 财政年份:2010
- 资助金额:
$ 159.31万 - 项目类别:
Regenerating Beta Cells by Lineage Reprogramming
通过谱系重编程再生β细胞
- 批准号:
8316302 - 财政年份:2010
- 资助金额:
$ 159.31万 - 项目类别:
Regenerating Beta Cells by Lineage Reprogramming
通过谱系重编程再生β细胞
- 批准号:
8717645 - 财政年份:2010
- 资助金额:
$ 159.31万 - 项目类别:
Regenerating Beta Cells by Lineage Reprogramming
通过谱系重编程再生β细胞
- 批准号:
7993955 - 财政年份:2010
- 资助金额:
$ 159.31万 - 项目类别:
Regenerating Beta Cells by Lineage Reprogramming
通过谱系重编程再生β细胞
- 批准号:
8466013 - 财政年份:2010
- 资助金额:
$ 159.31万 - 项目类别:
Regenerating Beta Cells by Lineage Reprogramming
通过谱系重编程再生β细胞
- 批准号:
8143353 - 财政年份:2010
- 资助金额:
$ 159.31万 - 项目类别:
Identification of Genes and Compounds That Control Beta Cell Replication
控制β细胞复制的基因和化合物的鉴定
- 批准号:
8044507 - 财政年份:2010
- 资助金额:
$ 159.31万 - 项目类别:
Pancreatic Islet Design & Engineering (SysCODE 3 of 10)
胰岛设计
- 批准号:
8070896 - 财政年份:2007
- 资助金额:
$ 159.31万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 159.31万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 159.31万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 159.31万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 159.31万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 159.31万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 159.31万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 159.31万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 159.31万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 159.31万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 159.31万 - 项目类别:














{{item.name}}会员




